| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma (NCT05137886) | Institute of Hematology & Blood Diseases Hospital, China | 2022-01-01 |
| RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT (NCT04776265) | Grupo Argentino de Tratamiento de la Leucemia Aguda | 2021-06-01 |
| Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) (NCT04268706) | Tessa Therapeutics | 2021-02-01 |
| Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis (NCT04758650) | Universitair Ziekenhuis Brussel | 2021-01-26 |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. (NCT04653649) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2020-09-29 |
| BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (NCT04378647) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2020-06-01 |
| First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) (NCT04638790) | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | 2020-02-01 |
| Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose (NCT04292626) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2020-01-19 |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study (NCT03260101) | Cellect Biotechnology | 2018-06-10 |
| Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy (NCT03535948) | Central Hospital, Nancy, France | 2018-05-15 |
| Physical Capacity in Hodgkin Lymphoma Survivors (NCT04636255) | University of Sao Paulo General Hospital | 2017-10-21 |
| PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma (NCT03155425) | Jiangsu HengRui Medicine Co., Ltd. | 2017-06-09 |
| Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma (NCT01578967) | UNC Lineberger Comprehensive Cancer Center | 2012-04-01 |
| Compassionate Use Re-Infusion of ATLCAR.CD30 (NCT03914885) | UNC Lineberger Comprehensive Cancer Center | |